Yes, Endo D is able to cleave glycans from some glycoproteins under native conditions if the glycan structure is trimmed to the trimannosyl core. For example, 10ugs of Rituximab (chimeric human/mouse IgG1 antibody) was incubated with the following glycosidases: 50 units of a2-3,6,8,9 Neuraminidase A (NEB #P0722 ), 8 units of b1-4 Galactosidase S (NEB #P0745), 8 units of β-N-Acetylglucosaminidase S (NEB #P0744 ) and 250 units of Endo D (NEB #P0742 ) in 1X Glycobuffer 1 and incubated overnight at 37°C. This resulted in complete removal of the glycan from the antibody.